BioCryst scores FDA approval on flu treatment for children
On the heels of an $80 million public offering, Research Triangle Park-based BioCryst Pharmaceuticals (Nasdaq: BCRX) has landed U.S. Food and Drug Administration approval for its injectable flu treatment in pediatric patients.
BioCryst submitted its supplemental new drug application for RAPIVAB (peramivir injection) earlier this year, with the FDA ultimately granting a priority review. In 2014, the FDA approved RAPIVAB for treating adults with the flu and the firm has also been approved in a number…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Biotechnology | Children | Food and Drug Administration (FDA) | Health Management | New Drug Applications | Pediatrics